The incidence rate of ILD/pneumonitis associated with other anti-HER2 ADCs ranged from 8 to 34.8% in previous studies28,31,33, whereas ILD/pneumonitis did not appear to be a safety signal that needed attention for FS-1502 in the current study. This evidence concerns the gene ERBB2 and interstitial lung disease.